Johnson & Johnson (NYSE:JNJ) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its stake in Johnson & Johnson (NYSE:JNJ) by 290.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,114,004 shares of the company’s stock after acquiring an additional 829,053 shares during the period. Johnson & Johnson accounts for approximately 1.3% of Handelsbanken Fonder AB’s holdings, making the stock its 8th biggest position. Handelsbanken Fonder AB’s holdings in Johnson & Johnson were worth $156,662,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Lincoln National Corp lifted its stake in Johnson & Johnson by 3.0% during the first quarter. Lincoln National Corp now owns 60,531 shares of the company’s stock valued at $7,937,000 after purchasing an additional 1,766 shares during the last quarter. Girard Partners LTD. lifted its stake in Johnson & Johnson by 1.1% during the first quarter. Girard Partners LTD. now owns 62,139 shares of the company’s stock valued at $8,148,000 after purchasing an additional 681 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Johnson & Johnson by 5.9% during the first quarter. Victory Capital Management Inc. now owns 2,757,100 shares of the company’s stock valued at $361,539,000 after acquiring an additional 152,727 shares during the period. First Horizon Advisors Inc. raised its holdings in shares of Johnson & Johnson by 0.7% during the first quarter. First Horizon Advisors Inc. now owns 100,935 shares of the company’s stock valued at $13,236,000 after acquiring an additional 735 shares during the period. Finally, Highland Capital Management LLC raised its holdings in shares of Johnson & Johnson by 514.5% during the first quarter. Highland Capital Management LLC now owns 109,807 shares of the company’s stock valued at $14,399,000 after acquiring an additional 91,939 shares during the period. 67.44% of the stock is owned by institutional investors.

Johnson & Johnson stock traded up $0.34 during trading hours on Tuesday, hitting $148.69. The company had a trading volume of 216,478 shares, compared to its average volume of 8,504,898. The firm’s fifty day moving average is $149.29 and its 200-day moving average is $144.17. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The firm has a market capitalization of $390.58 billion, a P/E ratio of 21.77, a price-to-earnings-growth ratio of 3.27 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Thursday, July 16th. The company reported $1.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company had revenue of $18.34 billion for the quarter, compared to analyst estimates of $17.73 billion. During the same quarter in the prior year, the business posted $2.58 EPS. Johnson & Johnson’s quarterly revenue was down 10.8% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 7.85 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a dividend of $1.01 per share. The ex-dividend date was Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.72%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.

A number of equities research analysts have recently issued reports on JNJ shares. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target on the stock. in a report on Tuesday, July 7th. Raymond James boosted their price target on shares of Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Citigroup boosted their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. Cantor Fitzgerald restated a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $163.00.

In related news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the sale, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: How do analysts define an oversold condition?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.